Company / Depreciation & Amortization
Vir Biotechnology, Inc. Depreciation & Amortization History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$11.7M
FY2025
5-year range
$3.3M / $19.5M
FY2021-FY2025
Trend
-19.8%
vs FY2024
Sector context
#59 of 168
Health Care
What the data says
At $12M, Vir Biotechnology, Inc.'s depreciation & amortization ranks #110 of 168 in the Health Care sector. Depreciation & Amortization has fluctuated over the past 9 years, ranging from $255,000 in FY2017 to $19M in FY2023.
Based on SEC 10-K filings.
$12M in FY2025 with a 5-year CAGR of +21.6%.
Improved from $19M to $12M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +38.5%
- 5-Year CAGR
- +21.6%
- 10-Year CAGR
- -
Sector benchmark
#110 of 168 in Health CareTop 65% of 168This company $11.7M Sector average $212.9M
▼
-94.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.6%, indicating consistent growth.
- In FY2025, depreciation & amortization decreased 19.8% year-over-year.
- Ranks #59 out of 168 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.7M | -19.8% |
| FY2024 | $14.6M | -25.2% |
| FY2023 | $19.5M | +342.1% |
| FY2022 | $4.4M | +33.6% |
| FY2021 | $3.3M | -25.1% |
| FY2020 | $4.4M | +33.6% |
| FY2019 | $3.3M | +103.6% |
| FY2018 | $1.6M | +534.5% |
| FY2017 | $255.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026